CN115943165A - Fc-CD80融合蛋白和其缀合物以及它们的用途 - Google Patents

Fc-CD80融合蛋白和其缀合物以及它们的用途 Download PDF

Info

Publication number
CN115943165A
CN115943165A CN202180037323.6A CN202180037323A CN115943165A CN 115943165 A CN115943165 A CN 115943165A CN 202180037323 A CN202180037323 A CN 202180037323A CN 115943165 A CN115943165 A CN 115943165A
Authority
CN
China
Prior art keywords
receptor
fusion protein
conjugate
antibody
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180037323.6A
Other languages
English (en)
Inventor
胡品良
邹敬
洪伟东
何芸
宋凌云
杨文第
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Beyond Biotechnology Co ltd
Original Assignee
Beijing Beyond Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Beyond Biotechnology Co ltd filed Critical Beijing Beyond Biotechnology Co ltd
Publication of CN115943165A publication Critical patent/CN115943165A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供了Fc‑CD80融合蛋白，其是在免疫球蛋白Fc结构域的C端连接有CD80胞外结构域(ECD)的融合蛋白。所述Fc‑CD80融合蛋白能够用于制备缀合物，所述缀合物包含所述Fc‑CD80融合蛋白作为第一组分、且包含含有第二效应分子的第二组分，所述第二组分位于第一组分的N端。本发明还提供了Fc‑CD80融合蛋白的缀合物，包含所述Fc‑CD80融合蛋白和/或缀合物的药物组合物，以及所述Fc‑CD80融合蛋白、缀合物或药物组合物用于在个体中治疗或预防癌性疾病的用途。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202180037323.6A 2020-05-25 2021-05-25 Fc-CD80融合蛋白和其缀合物以及它们的用途 Pending CN115943165A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010453172 2020-05-25
CN202010453172X 2020-05-25
PCT/CN2021/095750 WO2021238904A1 (zh) 2020-05-25 2021-05-25 Fc-CD80融合蛋白和其缀合物以及它们的用途

Publications (1)

Publication Number Publication Date
CN115943165A true CN115943165A (zh) 2023-04-07

Family

ID=78745574

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180037323.6A Pending CN115943165A (zh) 2020-05-25 2021-05-25 Fc-CD80融合蛋白和其缀合物以及它们的用途

Country Status (4)

Country Link
US (1) US20230235011A1 (zh)
CN (1) CN115943165A (zh)
AU (1) AU2021282053A1 (zh)
WO (1) WO2021238904A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117069856A (zh) * 2023-08-08 2023-11-17 北京翊博生物集团有限公司 双特异性抗体及应用、组合物、激活和扩增t细胞的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202405012A (zh) * 2022-04-02 2024-02-01 大陸商杭州尚健生物技術有限公司 Ｃｄ８０蛋白變體及ｃｄ８０融合蛋白
WO2024064754A1 (en) * 2022-09-20 2024-03-28 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted degradation and delivery of therapeutic agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005206478A (ja) * 2004-01-20 2005-08-04 Kirin Brewery Co Ltd 樹状細胞膜分子−ＩｇＦｃ融合ポリペプチドまたはそれに対する抗体を含む医薬組成物
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
WO2018201014A1 (en) * 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
CN109721657B (zh) * 2017-10-27 2021-11-02 北京比洋生物技术有限公司 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
JP7085644B2 (ja) * 2018-09-17 2022-06-16 ジーアイ・イノベイション・インコーポレイテッド Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117069856A (zh) * 2023-08-08 2023-11-17 北京翊博生物集团有限公司 双特异性抗体及应用、组合物、激活和扩增t细胞的方法
CN117069856B (zh) * 2023-08-08 2024-03-26 北京翊博生物集团有限公司 双特异性抗体及应用、组合物、激活和扩增t细胞的方法

Also Published As

Publication number Publication date
WO2021238904A1 (zh) 2021-12-02
US20230235011A1 (en) 2023-07-27
AU2021282053A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
US11746148B2 (en) Antibody molecules comprising a single-domain antigen-binding site and Fab fragments
JP7058213B2 (ja) 改変ｊ鎖を有する結合分子
CN109721657B (zh) 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
WO2018036473A1 (zh) 抗ctla4-抗pd-1双功能抗体、其药物组合物及其用途
WO2019062642A1 (zh) 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
WO2021238904A1 (zh) Fc-CD80融合蛋白和其缀合物以及它们的用途
CN109476747A (zh) 结合免疫调节性蛋白和肿瘤抗原的双特异性结合蛋白
US20220002408A1 (en) Bispecific antibody, preparation method thereof and application thereof
CN111423512B (zh) 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
JP2022513002A (ja) 抗ｐｄ－ｌ１／ｖｅｇｆ二機能性抗体およびその用途
US11529425B2 (en) Immunoconjugates comprising signal regulatory protein alpha
WO2021000530A1 (zh) 一种双特异性抗体及其制备方法与应用
CN111565738A (zh) 结合检查点阻碍物作为目标治疗的双功能性蛋白质
CN114616031A (zh) 对靶标密度高的细胞的选择性增强的多聚体抗体
CN111344019A (zh) 调节免疫检查点作为癌症治疗的单特异性与双特异性蛋白质
WO2023020537A1 (zh) 一种双特异性抗体及其用途
TW202108629A (zh) 用於t細胞活化之抗體
TW202104262A (zh) 結合pd-1的抗體
US11667704B2 (en) Anti-IL-17 antibody/TNFR ECD fusion protein and use thereof
WO2023045361A1 (zh) 抗tigit抗体与il2的融合蛋白或其变体及其应用
RU2652880C2 (ru) Антитело против рецептора эпидермального фактора роста
JP2023526448A (ja) ヒトｉｌ－１５変異体およびその使用
JP2023510806A (ja) Ｍａｉｔ及び腫瘍細胞の両方に結合する多重特異性抗体
CA3233075A1 (en) Interleukin-2 mutant and fusion protein thereof
CN115246885A (zh) 一种双特异性抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination